Circumcision: Circumcision performed as part of standard clinical care in patients with phimosis, which may be caused by lichen sclerosus. The procedure is not assigned by the study but observed as part of routine treatment
Study summary
This observational study aims to evaluate routine treatment outcomes in men with lichen sclerosus (LS), including a long-term follow-up to assess disease progression and histopathological changes. The study also investigates potential risk factors for LS and the disease's impact on quality of life and sexual health.
Eligibility
Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria for patients with LS (LS Urology and LS dermatology):
* Biologically male
* ≥18 years old
* Referred to the dermatology department or the urology department in Västerbotten and diagnosed with LS.
* Must be able to read and write Swedish to fill in questionnaire and informed consent.
Inclusion criteria for control group "Controls - Urology":
* Biologically male
* ≥18 years old
* Phimosis without LS, treated with circumcision at the urology department in Västerbotten
* Must be able to read and write Swedish to fill in questionnaire and informed consent.
Inclusion criteria for control group "Controls - General Population":
* Biologically male with male genitalia
* ≥18 years old
* No genital symptoms
* Must be able to read and write Swedish to fill in questionnaire and informed consent.
Exclusion Criteria for all groups:
* Age under 18 years old
* Not able to read and write in Swedish.
* Unable to leave an informed consent to participate.
Primary outcome measure(s)
Long-term clinical outcome of treatment for lichen sclerosus — baseline, 1 year, 3 years, 5 years, 10 years Assessment of symptom resolution, recurrence, and need for additional treatment over a follow-up period of up to 10 years, based on clinical assessment and patient-reported outcomes. The severity of the disease will be graded on a four point scale 0-3 (0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms, 3 = severe symptoms)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
